← vista completa

Published on May 1, 2009 | http://doi.org/10.5867/medwave.2009.05.3915

New drug options in dyslipidemias

Nuevas alternativas farmacológicas en dislipidemias

Robert Eckel

This work is licensed under a Creative Commons Attribution 4.0 International License. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Authors

Robert Eckel

School of Medicine, University of Colorado, Denver, Estados Unidos

Figures

Article has no figures.

Forum

No messages

History

Citation Eckel R. New drug options in dyslipidemias. Medwave 2009;9(05):e3915 doi: 10.5867/medwave.2009.05.3915

Submission date 01/01/1970

Acceptance date 01/01/1970

Publication date 01/05/2009

Index

Metrics

Not available at the moment.

Notes

References

  1. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986 Nov 28;256(20):2823-8. | CrossRef | PubMed
  2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 May 16;285(19):2486-97. | CrossRef | PubMed
  3. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004 Jul 13;110(2):227-39. | CrossRef | PubMed
  4. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008 Apr 3;358(14):1431-43. Epub 2008 Mar 30. | CrossRef | PubMed
  5. Mabuchi H, Koizumi J, Shimizu M, Kajinami K, Miyamoto S, Ueda K, et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol. 1998 Dec 15;82(12):1489-95. | CrossRef | PubMed
  6. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease--the Framingham Heart Study. Can J Cardiol. 1988 Jul;4 Suppl A:5A-10A. | PubMed
  7. Capell WH, Eckel RH. Severe hypertriglyceridemia with a history of treatment failure. Nat Clin Pract Endocrinol Metab. 2005 Nov;1(1):53-8; quiz 59. | CrossRef | PubMed
  8. Bloomfield HE. The role of fibrates in a statin world. Arch Intern Med. 2006 Apr 10;166(7):715-6. | CrossRef | PubMed
  9. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000 Jul 4;102(1):21-7. | PubMed
  10. Robins SJ, Rubins HB, Faas FH, Schaefer EJ, Elam MB, Anderson JW, et al. Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care. 2003 May;26(5):1513-7. | CrossRef | PubMed
  11. Taylor A, Sullenberger L, Lee H, Lee J, Grace K. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004; 110: 3512-7. | CrossRef | PubMed | Link
  12. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007 Sep 27;357(13):1301-10. | CrossRef | PubMed
  13. Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006 Sep 9;368(9539):919-28. | CrossRef | PubMed
  14. Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation. 2008 Jan 15;117(2):176-84. Epub 2007 Dec 17. | CrossRef | PubMed